Pretreatment immunoscore and an inflamed tumor microenvironment (TME) are associated with efficacy in patients (Pts) with refractory large B cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel) in ZUMA-1

被引：7

作者：

Rossi, John M. ^{[1
]}

Galon, Jerome ^{[2
]}

Chang, Edmund ^{[1
]}

Perbost, Regis ^{[3
]}

Scholler, Nathalie ^{[1
]}

Turcan, Sarah ^{[3
]}

Danan, Corinne ^{[3
]}

Locke, Frederick L. ^{[4
]}

Neelapu, Sattva S. ^{[5
]}

Miklos, David B. ^{[6
]}

Jacobson, Caron A. ^{[7
]}

Lekakis, Lazaros J. ^{[8
]}

Lin, Yi ^{[9
]}

Ghobadi, Armin ^{[10
]}

Milletti, Francesca ^{[1
]}

Go, William Y. ^{[1
]}

Bot, Adrian ^{[1
]}

机构：

[1] Kite, Santa Monica, CA USA

[2] UPMC Univ Paris, Sorbonne Univ, Univ Paris Descartes, INSERM, Marseille, France

[3] HalioDx, Paris, France

[4] H Lee Moffitt Canc Ctr & Res Inst, Blood & Marrow Transplantat, Tampa, FL USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[6] Stanford Univ, Sch Med, Blood & Marrow Transplantat, Stanford, CA 94305 USA

[7] Dana Farber Canc Inst, Boston, MA 02115 USA

[8] Univ Miami Hlth Syst, Sylvester Comprehens Canc Ctr, Miami, FL USA

[9] Mayo Clin, Div Hematol, Rochester, MN USA

[10] Washington Univ, Sch Med, Div Med Oncol, St Louis, MO USA

来源：

CANCER RESEARCH | 2019年 / 79卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2019-CT153

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT153

引用

页数：3

共 50 条

[41] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/ Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)
Oluwole, Olalekan O.
Forcade, Edouard
Muñoz, Javier
de Guibert, Sophie
Vose, Julie M.
Bartlett, Nancy L.
Lin, Yi
Deol, Abhinav
McSweeney, Peter A.
Goy, Andre H.
Kersten, Marie Jose
Jacobson, Caron
Farooq, Umar
Minnema, Monique C.
Thieblemont, Catherine
Timmerman, John M.
Stiff, Patrick
Avivi, Irit
Tzachanis, Dimitrios
Kim, Jenny J.
Zheng, Yan
Shen, Rhine R.
Vardhanabhuti, Saran
Van Meerten, Tom
BLOOD, 2021, 138
[42] Pretreatment (PreTx) immune cell phenotypes in peripheral blood associated with the tumor immune contexture, product attributes, and durable clinical efficacy in patients with large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel).
Budka, Justin
Chou, Justin
Plaks, Vicki
Milletti, Francesca
Wang, Zixing
Locke, Frederick L.
Neelapu, Sattva S.
Miklos, David B.
Jacobson, Caron A.
Lekakis, Lazaros J.
Lin, Yi
Ghobadi, Armin
Bashir, Zahid
Scholler, Nathalie
Galon, Jerome
Rossi, John M.
Bot, Adrian
CANCER RESEARCH, 2021, 81 (13)
[43] Dynamic changes in the tumor microenvironment from initial diagnosis through sequential therapies in patients with large B cell lymphoma undergoing axicabtagene ciloleucel (axi-cel) treatment
Mattie, Michael
Perbost, Regis
Auguste, Aurelie
Turcan, Sarah
Kim, Jenny J.
To, Christina
Nater, Jenny
Filosto, Simone
Shen, Rhine R.
Galon, Jerome
CANCER RESEARCH, 2024, 84 (07)
[44] The Phase 3, Randomized Study of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma: ZUMA-7
Schmitz, N.
Oluwole, O. O.
Bishop, M. R.
Gisselbrecht, C.
Gordon, L. I.
Kersten, M. J.
Maloney, D. G.
Caballero, M. D.
Kuruvilla, J.
Song, K. W.
Jacobson, C. A.
Nastoupil, L. J.
Riedell, P.
Jiang, Y.
Rossi, J. M.
Lee, L.
Cheng, P.
Locke, F. L.
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 90 - 91
[45] CLINICAL AND BIOLOGIC COVARIATES OF OUTCOMES IN ZUMA-1: A PIVOTAL TRIAL OF AXICABTAGENE CILOLEUCEL (AXI-CEL; KTE-C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON-HODGKIN LYMPHOMA (NHL)
Locke, F. L.
Neelapu, S. S.
Bartlett, N. L.
Lekakis, L. J.
Miklos, D.
Jacobson, C. A.
Braunschweig, I.
Oluwole, O.
Siddiqi, T.
Lin, Y.
Timmerman, J.
Reagan, P. M.
Bot, A.
Rossi, J.
Navale, L.
Jiang, Y.
Aycock, J.
Elias, M.
Wiezorek, J.
Go, W. Y.
HAEMATOLOGICA, 2017, 102 : 172 - 172
[46] Axicabtagene Ciloleucel (Axi-Cel) versus standard-of-care therapy in patients with relapsed/refractory diffuse large B cell lymphoma: The phase 3, randomized study, ZUMA-7
Schmitz, N.
Oluwole, O. O.
Bishop, M. R.
Gisselbrecht, C.
Gordon, L. I.
Kersten, M. J.
Maloney, D. G.
Caballero, M. D.
Kuruvilla, J.
Song, K. W.
Jacobson, C. A.
Nastoupil, L. J.
Riedell, P.
Jiang, Y.
Rossi, J. M.
Lee, L.
Cheng, P.
Locke, F. L.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 47 - 47
[47] Axicabtagene Ciloleucel (Axi-Cel) versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: ZUMA-7, A Phase 3, Randomized Study
Oluwole, Olalekan O.
Bishop, Michael R.
Gisselbrecht, Christian
Gordon, Leo I.
Kersten, Marie Jose
Maloney, David G.
Schmitz, Norbert
Dolores Caballero, Maria
Kuruvilla, John
Song, Kevin W.
Jacobson, Caron A.
Nastoupil, Loretta J.
Riedell, Peter
Jiang, Yizhou
Rossi, John M.
Lee, Lillian
Cheng, Paul
Locke, Frederick L.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S293 - S294
[48] Durability of Response in ZUMA-1, the Pivotal Phase 2 Study of Axicabtagene Ciloleucel in Patients With Refractory Large B-Cell Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (08) : 16 - 18
[49] Resource Utilization and Factors Prolonging Hospitalization for Patients with Refractory and Relapsed B-Cell Lymphoma Receiving Axicabtagene Ciloleucel (Axi-cel)
Mian, Agrima
Wei, Wei
Hill, Brian T.
Hamilton, Betty K.
Pohlman, Brad
Jagadeesh, Deepa
Anwer, Faiz
Kalaycio, Matt E.
Dean, Robert M.
Sobecks, Ronald M.
Majhail, Navneet S.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S44 - S45
[50] A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma
Neelapu, Sattva S.
Locke, Frederick L.
Bartlett, Nancy L.
Lekakis, Lazaros J.
Reagan, Patrick M.
Miklos, David B.
Jacobson, Caron A.
Braunschweig, Ira
Oluwole, Olalekan O.
Siddiqi, Tanya
Lin, Yi
Crump, Michael
Kuruvilla, John
Van den Neste, Eric
Farooq, Umar
Navale, Lynn
DePuy, Venita
Kim, Jenny J.
Gisselbrecht, Christian
BLOOD, 2019, 134

← 1 2 3 4 5 →